Q-omics provides the consensus-scored ROMO1 profile across patient tissues and cancer cell-line models. ROMO1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ROMO1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ROMO1 RNA expression shows 19,371 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where ROMO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ROMO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ROMO1 survival associations across molecular data types. ROMO1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ROMO1 RNA expression–survival associations across cancer types. High ROMO1 expression shows unfavorable associations in UVM, HNSC, KICH, ACC, LGG and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ROMO1 RNA expression.
This table summarizes ROMO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ROMO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ROMO1 shows higher tumor expression in KIRC, BLCA, LIHC, COAD, HNSC and KIRP. The KIRC box plot shows higher ROMO1 RNA expression in tumor versus normal tissue (log2 FC = +0.729, t-test p < 0.001).
This table shows molecular features associated with ROMO1 in patient tissues and cancer cell lines. In patient samples, ROMO1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ROMO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
